{
  "id": 12976351,
  "title": "Relay Therapeutics CFO Catinazzo sells $329k in shares",
  "url": "https://urgent.news/2026/10/08/relay-therapeutics-cfo-catinazzo-sells-329k-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T22:45:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/relay-therapeutics-cfo-catinazzo-sells-329k-in-shares-93CH-4939948"
  },
  "original_language": "en",
  "account": "Thomas Catinazzo, the CFO of Relay Therapeutics, sold 17,717 shares of the company's stock on October 6, 2026. The sales were made under a pre-planned trading strategy, and took place at prices between $18.20 and $19.27 per share. This amounted to a total of roughly $329,321. The transactions were divided into two categories - 17,511 shares sold at an average price of $18.58, and an additional 206 shares sold at an average price of $19.26. Following the sale, Catinazzo still owns 105,134 shares in the company, including 6,538 shares tied to restricted stock units. This comes as the company's stock has risen nearly 185% over the past year, currently at $17.41. Despite this insider sale, analysts remain bullish on Relay Therapeutics. Several firms have raised their price targets, and raised their rating for the stock. This includes H.C. Wainwright and Citizens, both of which upgraded their rating to Buy.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}